AcuCort’s patent is granted with 1,349 days extended patent protection in the US
AcuCort AB (AktieTorget: ACUC) today announces that the US Patent and Trademark Office (USPTO) has granted the company’s patent application for the medical formulations containing glucocorticoids for self-treatment in acute situations, “Acute Glucocorticoid Therapy”. In addition, the authority extends the duration of the patent by 1,349 days.
The US patent no. 9,925,139, B2 describes medical self-treatment with glucocorticoids in emergency situations without access to medical personnel. The patent protected invention describes and covers glucocorticoids in general, which means that the protection against competition will be wider and stronger than the specific composition of the company’s pharmaceutical drug Dexa ODF which is a fast-dissolving film to be placed on the tongue. The invention has previously resulted in granted patents for AcuCort in 30 countries.
In accordance with US patent law, when the patent authority has caused a delayed approval, the USPTO has extended the patent term and patent protection has thus been extended until January 1, 2028.
“More than a billion people suffer from allergies worldwide. Dexa ODF may offer important treatment for many allergics in emergency situations. Patent protection in the US, the world's largest pharmaceutical market, is a strategically essential component in the commercialization of Dexa ODF,” says Mats Lindfors, CEO of AcuCort.
About glucocorticoids
Every year millions of patients across the world use medicines containing glucocorticoids, for example against allergy and viral croup. Also cancer patients suffering from nausea and vomiting in connection with chemotherapy (CINV) use this type of drug. One big disadvantage is that these drugs are not perceived to be user-friendly or require medical staff. First having to dissolve the tablets in water can be very awkward in an acute situation, for the sufferers as well as for other persons helping them. The sufferer may have difficulties swallowing, and thus a fast-dissolving film to be placed on the tongue, with the same effect as the tablet, may have a wide application area.
This information is information that AcuCort AB is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact person below on April 16, 2018.
For more information
Mats Lindfors, CEO, AcuCort AB
Mobile: +46 70 790 58 15
E-mail: mats.lindfors@acucort.se
About AcuCort
AcuCort develops and commercializes Dexa ODF, a fast-dissolving oral film containing the glucocorticoid dexamethasone. Dexa ODF is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of acute allergic reactions, viral croup in children and chemotherapy-induced nausea and vomiting (CINV). Dexa ODF is estimated to have a short time to market as the company only has to repeat a previously successful bioequivalence study before applying for market approval in Europe. Please visit www.acucort.se
Tags: